#Biotechnology
LightNews LightNews
reuters.com
James D. Watson, the brilliant but controversial American biologist whose 1953 discovery of the structure of DNA ushered in the age of genetics and provided the foundation for the biotechnology revolution of the late 20th century, died at age 97 reut.rs/4ou5MZL
November 7, 2025 at 8:18 PM
cenmag.bsky.social
Arena BioWorks, an ambitious biotechnology firm founded last year by several science heavyweights, has shut down, according to a company press release on Tuesday. cen.acs.org/pharmaceutic... #chemsky 🧪
Billionaire-backed Arena BioWorks closes less than 2 years after launch
The company aimed to be a privately funded equivalent to the Broad Institute
cen.acs.org
November 7, 2025 at 9:52 PM
bikinhog.bsky.social
--symbiotic, plant-based "biotechnology" to match the constant advances and frightening biomagicks of the Ul-Haran; ultimately being the cause of their emergence as a world superpower.

Most of the power needed for such advanced magics--and to make them fully practical for military applications--
November 10, 2025 at 2:58 PM
xianinnovbiotech.bsky.social
Xi'an Innov Biotechnology Co., Ltd. specializes in high-quality health ingredients, including plant extracts and functional raw materials like liposomal glutathione. With a strong focus on innovation and sustainability, we provide custom solutions to global markets.
November 9, 2025 at 6:29 PM
csbj.org
🔗 Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: doi.org/10.1016/j.cs...

📚 CSBJ: www.csbj.org

#MonoclonalAntibodies #mAbs #Immunology #MolecularDynamics
Single-residue engineering of lambda (λ) antibody light chains reduces conformational flexibility and enhances thermal stability. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.10.045
November 10, 2025 at 8:45 AM
davidmcwatters.bsky.social
Our new paper is out now in Nature Biotechnology!
November 5, 2025 at 2:41 PM
tum.de
Misfolded proteins can cause #Alzheimers, #Parkinsons and #Cancer. Johannes Buchner, part of the CHAPEROME team, receives an #ERC Synergy Grant to study how chaperone #proteins keep cells healthy: go.tum.de/904052 👏

#ERCSyG #biotechnology
@erc.europa.eu

📷A. Heddergott
Highly endowed ERC Synergy Grant for Prof. Johannes Buchner
Disease-causing proteins – ERC Synergy Grant for research at TUM on the role of chaperone “helper proteins.”
go.tum.de
November 6, 2025 at 11:53 AM
marhecenter.bsky.social
MaRHE Center researchers joined the 2nd CRIMAC International School – SymbioMar 🪸 in Amendolara, Italy.
An inspiring event on marine symbiosis — from taxonomy to biotechnology.
Thanks to @calabria.marine_centre_crimac for hosting! 🌊
#MarineScience #Symbiosis
November 10, 2025 at 9:31 AM
thegodwinexx.bsky.social
Turns out we can harness apomixis to develop self-reproducing sorghum hybrids. Our newly published paper with Corteva Agriscience @cortevaagriscience.bsky.social
Paper available in Plant Biotechnology Journal today: doi.org/10.1111/pbi.... 🧪
November 6, 2025 at 2:00 AM
pablocarb.bsky.social
I am happy to announce the launch of our seminar series “Microbial Biotechnology: Developing the Conceptual Framework of the DBTL Cycle.” We invite you to join us and engage in shaping the future of biomanufacturing! researchseminars.org/seminar/Micr...
researchseminars.org - View series
Welcome to researchseminars.org, a list of research seminars and conferences!
researchseminars.org
November 6, 2025 at 9:19 PM
gotmyniinaa.bsky.social
"Whereas first-wave eugenicists strove to improve the “human stock” by altering society-wide patterns of reproduction [...], second-wave eugenics arose in response to new technological possibilities associated with genetic engineering and biotechnology"
November 4, 2025 at 9:20 AM
iamkawa.bsky.social
Maybe Rian will feel a sense of ease and instant connection if he gets to know Viktor. Rather than being surprised or embarrassed, he will naturally accept another being who looks like a twin. While studying biotechnology, Rian got used to accepting mysterious phenomena as they are🤣
November 6, 2025 at 6:03 AM
aryngve.bsky.social
Scientists claim to have revived the nervous systems of dead animals in experiments.

Are we ready for a future where death can be reversed?

In this essay I argue that society cannot handle such a profound change:
aryngve.substack.com/p/land-of-th...

#science #future #biotechnology
LAND OF THE DEAD: A possible future scenario
Submitted for your consideration
aryngve.substack.com
November 8, 2025 at 12:43 PM
scienceinvancouver.com
Seven start-up ventures founded by UBC Faculty of Medicine community members have joined the 50th cohort of UBC’s Venture Founder program to help address global challenges in areas including biotechnology and health care.

See the 7 teams: https://bit.ly/43UJ0Ss

#VancouverBiotech
November 7, 2025 at 1:59 AM
lessonpills.bsky.social
🧬 New C1 lesson PDF: Biotechnology and the future of healthcare
🔤 Grammar → Expressing certainty and doubt
📚 Vocabulary → Biotechnology and ethics
📎 Download: https://www.lessonpills.com/future-medicine-biotechnology-ethical-debate/
🧬 New C1 lesson PDF: Biotechnology and the future of healthcare 🔤 Grammar → Expressing certainty and doubt 📚 Vocabulary → Biotechnology and ethics 📎 Download: https://www.lessonpills.com/future-medicine-biotechnology-ethical-debate/
November 4, 2025 at 12:00 PM
rcnews.bsky.social
VTT identifies new plant-based anti-inflammatory and anti-ageing ingredients for sustainable cosmetics  renewable-carbon.eu/news/?p=169876 #biotechnology #cosmetics #phytopharmaceuticals #plantbased #skincare #RenewableCarbon
November 5, 2025 at 9:45 AM
startupnews.bsky.social
“From Birthplace of Jazz, Startup Swings with Non-Opioid Pain Treatments” — Genetic Engineering and Biotechnology News

#StartupNews #Startup #Startups
White text on a brown background reads, “From Birthplace of Jazz, Startup Swings with Non-Opioid Pain Treatments”. Underneath, Genetic Engineering and Biotechnology News is listed as the source.
November 4, 2025 at 8:49 PM
uji.es
🆕🍊 GEA BIOTECHNOLOGY revoluciona el sector citrícola amb la nova mandarina “Mina” presentada a l'UJI.

https://f.mtr.cool/pqhlyfpmiv
November 4, 2025 at 5:02 PM
ukdefencejournal.org.uk
NATO Secretary General Mark Rutte has urged allied nations to accelerate innovation and investment in biotechnology to ensure the alliance remains ahead of rivals such as China and Russia, the organisation stated.
ukdefencejournal.org.uk/?p=63572
NATO warns against losing biotech edge to China and Russia
NATO Secretary General Mark Rutte has urged allied nations to accelerate innovation and investment in biotechnology to ensure the alliance remains ahead of rivals such as China and Russia, the organisation stated.
ukdefencejournal.org.uk
November 1, 2025 at 11:01 AM
csbj.org
💡 Can AI find the viral “on switch” that triggers infection?

🔗 Machine and deep learning to predict viral fusion peptides. Computational and Structural Biotechnology Journal, DOI: doi.org/10.1016/j.cs...

📚 CSBJ: www.csbj.org

#MachineLearning #Virology #AI #ProteinEngineering #Bioinformatics
Machine and deep learning to predict viral fusion peptides. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.02.011
November 1, 2025 at 11:51 PM
phileil.bsky.social
Of course, this being America in 2025, there's a creepy techno-capitalist angle to this (already weird) story.

A more accurate headline might be "Tom Brady Uses Cloned Dog to Shill for Tech Company He Invests In That's Trying to Make 'Jurassic Park' Happen in Real Life."
Text that reads; The former New England Patriots quarterback is an investor with Colossal, a Texas-based biotechnology company that is attempting to bring back extinct species like the woolly mammoth. "A few years ago, I worked with Colossal and leveraged their non-invasive cloning technology through a simple blood draw of our family's elderly dog before she passed," Brady said in a statement. "In a few short months, Colossal gave my family a second chance with a clone of our beloved dog."
November 5, 2025 at 1:03 PM
pintiucom.bsky.social
Understanding the Complexity of Gene Therapy
How is AI Revolutionizing Gene Therapy? #AIinHealthcare #artificialintelligence #Biotechnology #CRISPR #drugdiscovery #GeneTherapy #GeneticEngineering #Genomics #machinelearning
pintiu.com/ai-best-tool...
German
October 30, 2025 at 5:32 PM
csbj.org
🔗 RoseTTAFold diffusion-guided short peptide design: a case study of binders against Keap1/Nrf2. Computational and Structural Biotechnology Journal, doi.org/10.1016/j.cs...

📚 CSBJ: www.csbj.org

#StructuralBiology #PeptideTherapeutics #RoseTTAFold #ProteinEngineering #MolecularDynamics #DrugDesign
RoseTTAFold diffusion-guided short peptide design: a case study of binders against Keap1/Nrf2. Computational and Structural Biotechnology Journal, DOI: https://doi.org/10.1016/j.csbj.2025.02.032
October 31, 2025 at 12:35 AM
kathleenclark.bsky.social
The facts alleged in this civil complaint are damning.

Any ethics advisor would have told Tidmarsh to recuse from matters involving these companies because of his history with them and his financial ties to their owner.

Did he ignore their advice, or …

storage.courtlistener.com/recap/gov.us...
Case 1:25-cv-03593 Document 1 Filed 11/02/25 Page 15 of 32 Dr. Tidmarsh assumes leadership of FDA's CDER and immediately sets out to harm Mr. Tang's business interests and extort and solicit a bribe from Mr. Tang 53. On July 21, 2025, Dr. Tidmarsh was appointed Director of FDA's CDER, which is responsible for reviewing, approving, and regulating most prescription and over-the-counter drugs marketed in the U.S., and, where necessary, removing or otherwise restricting the marketing of such drugs. 54. On July 31, 2025, Dr. Tidmarsh's personal lawyer, Joseph Galda, emailed Mr. Tang about Dr. Tidmarsh's services agreement with American Laboratories (referred to as ALI). After explaining that Dr. Tidmarsh was legally required to divest himself of any interest in American Laboratories, Mr. Galda's email stated: "[Dr. Tidmarsh's) services having been completed, he has assigned the right to receive payments (to] Virello Group, LLC, which is a limited liability company managed by me for the benefit of each of his three sons." Mr. Galda then asked that future payments under Dr. Tidmarsh's services agreement be sent to him. The following day, Dr. Tidmarsh emailed Mr. Tang to confirm the instructions in Mr. Galda's July 31, 2025 email. 15 Case 1:25-cv-03593 Document 1 Filed 11/02/25 Page 16 of 32 Outlook Re: Dr. Tidmarsh and ALI From George Tidmarsh Date Tri 8/1/2025-4.17 AM To Joseph P. Galda Kevin lang Thank you JP. I can confirm these instructions On Jul 31, 2025, at 21:19, Joseph P. Galda Mr. Tang: Sorry for the typo. I meant in care of Best, JPG| JOSEPH P. GALDA J.P. Galda & Co. 40 East Montgomery Avenue, LTW 220 Ardmore, PA 19003 M:+ wrote: From: Joseph P. Galda Date: Thursday, July 31RE2K0EIKRSA2M To: kevin Cc: George Fa lamarsh, M.D. Ph.D. Subject: Dr. Tidmarsh and ALI Mr. Tang: As I'm sure you know, Dr. Tidmarsh has begun his duties at the Food and Drug Administration which require his divestiture of all interests in pharmaceutical and biotechnology companies and in that connection his right to receive payment under the services agreement with a ALI. His services having been completed, he has assigned the right to receive payments Virello Group, LL.C, which is a limited liability company managed by me for the benefit of each of his three sons. Please direct payments to not care of J.P. Gaida & Co., 40 E. Montgomery Ave., LTW 220, Ardmore, PA 19003. Recognizing the need to assure you that this is his instruction, I am asking him to return confirmation to this email. Should have any question in this regard, please call me at Kind regards, JPG (See Exhibit 11.) 55. Given his new position, Dr. Tidmarsh should have been focused on advancing public health and wellbeing. Instead, he immediately set out abusing his position to harm 60. Dr. Tidmarsh was not content to stop there, though. Having pushed FDA to chcwwclstcr.ocw.wewtowt.chetw.chaho.whrcalchcotocwnoilntsohswnchic.t.@0xthk@ut Case 1:25-cv-03593 Document Filed 1102125 Page 180132 Dr. Tadmarsh immediately set out to protit personally from those actions by demanding payment from Mr. Tang 61. Days after FDA's announcement, Dr. Tidmarsh directed his personal lawyer, Mr Galda, to email Mr. Tang and request that American Laboratories (referred to as ALL) extend a pre-existing services agreement with Dr. Tidmarsh "for another 10 years" in light of the fact "that) ALl may have issues that roquire an extension of the services agrocment —a statement that only can be construed as reterencing MDA's recent announoement that it was taking action to ellectively) remove DTE from the market. Under Dr. Tidmarsh's proposal, American Laboratorics now would be required to make payments until the ycar 2044 into a Dr. Tidmarsh-associated entity. This August 28. 2025 cmail from Mr. Galda to Mr. Tang, titlod "Agroement with Dr. Tidmarsh," reads as lollows: Agreement with Dr. Tidmarshl Date Thu 8/28/2025 12.08 PM| Khwhtamo Kevin: Ihope this linds you well. It is my understanding that ALl may have issues that require an extension o the services agreement. Accordingly, we propose to extend the services agreement for another 10 years.. Please let me know il this is acceptable and & so. I will prepare the assocated paperwork 62. The imbort of Mir, Galda's uncolicitod and unprovoked email could not have bccni clearer: Dr. Tidmarsh wanted a navout in exchange for usine his authority as CDER Diroctor tol help mitigate the obvious harm to American Laboratorics, Tang Capital, and Mr. Tang from the Case 1:25-cv-03593 Document 1 Filed 11/02/25 Page 21 of 32 approved for marketing in the U.S. by FDA in 2021 and is now approved in 37 countries around the world, including, but not limited to, all of the countries in the Europcan Union, Great Britain, and Japan. Dr. Tidmarsh published false and damaging statements that he knew were false at the time he made them Despite knowing that voclosporin has demonstrated direct clinical benefit-and in total disregard of the patients suffering from lupus nephritis and benefiting from treatment with voclosporin on the morning of September 29, 2025, Dr. Tidmarsh published a post on his personal Linkedin page, falsely claiming that voclosporin "has not been shown to provide a direct clinical benefit for patients" and asserting that Aurinia had failed "to perform the trials necessary to confirm actual clinical benefit" from voclosporin: George F Tidmarsh [3 - 1st 2h • © CDER will be evaluating surrogate endpoints used for FDA approval. While there is no doubt that the use of such endpoints has benefited patients by bringing valuable treatments to patients sooner, there have been notable failures in confirmatory trials, such as those for exon skiptang therapies in UMD. Ark tor some crseases. such as lupus nephritis, companies have not run trials to progression to end stage renal disease. So we have approved drugs with significant toxicity like vocolosporin that has not been shown to provide a direct clinical use of surrogate endpoints to see where we can further companies to perform the trials necessary to confirm 71. (See Exhibit 14.) The post clearly referred to Plaintiffs, as Aurinia owns the only FDA-approved voclosporin product and Aurinia US is the sole marketer and distributor of voclosporin in the U.S.
November 3, 2025 at 6:58 AM